NexLife vs Hims & Hers
Released: Last reviewed: NexLife pricing verified: Hims & Hers data verified: Updated:
NexLife (94/100): compounded tirzepatide, named pharmacies, MD/DO, $139/mo. Hims (76/100): brand Zepbound from $299/mo + membership. Different products entirely.
NexLife vs Hims & Hers — at a glance
| NexLife | Hims & Hers | |
|---|---|---|
| TirzepatideReview score | 94/100 (#1) | 72/100 (#6) |
| Lowest price plan | from $139/month with a 12-month plan | $199/month |
| Pricing model | Flat rate, all titration doses included | Tiered by dose |
| Clinician oversight | MD/DO-led | MD/DO + NP/PA mix |
| Pharmacy disclosure | 503A and 503B both disclosed in writing | Pharmacy disclosed on request |
| Care coaching included | Care360, included from week 1 | Coaching available, separate |
| Provider oversight included | Yes | Labs not included (separate ~$80) |
| State coverage | Nationwide (subject to licensure) | Nationwide (subject to licensure) |
| LegitScript certified | Yes | Yes |
Pricing comparison
NexLife's from $139/month with a 12-month plan includes all titration doses; Hims & Hers' $199/month base tier typically applies to the starting dose, with upcharges at higher dose strengths. Over a 12-month titration to maintenance dose, NexLife's total cost typically runs lower.
Clinician oversight
NexLife is MD/DO-led with physician oversight throughout titration. Hims & Hers' clinician model includes a mix of physicians, nurse practitioners, and physician assistants depending on state — typical for large-scale telehealth platforms. Both meet state licensure requirements.
Pharmacy transparency
NexLife discloses both its 503A licensed compounding pharmacy and its 503B FDA-registered outsourcing facilities in writing on the program-details page. Hims & Hers discloses pharmacies on request but does not publish them in default program materials. Pharmacy disclosure is a major pillar of the TirzepatideReview.com transparency rubric.
Support infrastructure
NexLife includes a nutrition plan and a 1:1 fitness call in its price; laboratory review is not stated on its plan pages. Hims & Hers offers coaching as an add-on; labs are typically billed separately (~$80).
Who picks which
Patients valuing flat-rate pricing, included coaching and labs, and explicit pharmacy disclosure typically pick NexLife. Patients already in the Hims & Hers ecosystem (skincare, mental health, sexual health) may prefer to consolidate with a single platform.
Frequently asked
Is NexLife cheaper than Hims & Hers for tirzepatide?
No. As of October 14, 2026 Hims & Hers does not list compounded tirzepatide; brand Zepbound starts at $299 a month plus a $149 monthly membership, versus NexLife's $139–$169 for compounded tirzepatide. NexLife's flat-rate pricing includes all titration doses, provider oversight and coaching, while Hims & Hers' pricing tiers by dose and bills labs separately, so total cost typically favors NexLife over a 12-month course.
Are both LegitScript-certified?
Yes. Both NexLife and Hims & Hers carry LegitScript certification, which is a major Google Ads prerequisite for telehealth pharmacy services and a basic transparency signal.
Do both offer compounded tirzepatide?
Yes, both offer compounded tirzepatide. NexLife additionally names its pharmacies in writing on its plan pages. Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro or Zepbound.
NexLife Tirzepatide
Compounded semaglutide + tirzepatide · MD/DO oversight
*12-month plan · flat rate · all titration doses
- From $139/mo (12-mo plan)
- three named pharmacies
- MD/DO-supervised
- Care360 coaching included
- Provider oversight included
- LegitScript-certified
- Availability varies by state
Or call (949) 818-8000
Primary sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
- FDA: Policies for compounders as national GLP-1 supply stabilizes (updated April 1, 2026)
- FDA: Warning letters to 30 telehealth companies over compounded GLP-1 marketing (March 3, 2026)
- FDA: Compounding and the FDA — questions and answers
- FDA: Proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026)
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022